BUDZ Quote, Financials, Valuation and Earnings

Cencora has a net margin of -- compared to Weed's net margin of 0.95%. Weed's return on equity of -- beat Cencora's return on equity of 183.42%.

Weed has a consensus price target of --, signalling downside risk potential of --. On the other hand Cencora has an analysts' consensus of $317.09 which suggests that it could grow by 9.26%. Given that Cencora has higher upside potential than Weed, analysts believe Cencora is more attractive than Weed.

Weed has a beta of 0.835, which suggesting that the stock is 16.517% less volatile than S&P 500. In comparison Cencora has a beta of 0.604, suggesting its less volatile than the S&P 500 by 39.596%.

Weed has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Cencora offers a yield of 0.74% to investors and pays a quarterly dividend of $0.55 per share. Weed pays -- of its earnings as a dividend. Cencora pays out 27.58% of its earnings as a dividend. Cencora's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Weed quarterly revenues are --, which are smaller than Cencora quarterly revenues of $75.5B. Weed's net income of -$95.9K is lower than Cencora's net income of $717.9M. Notably, Weed's price-to-earnings ratio is 180.00x while Cencora's PE ratio is 33.67x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Weed is -- versus 0.18x for Cencora. Usually stocks with elevated PS ratios are considered overvalued.

Standard BioTools has a net margin of -- compared to Weed's net margin of -63.81%. Weed's return on equity of -- beat Standard BioTools's return on equity of -26.52%.

Weed has a consensus price target of --, signalling downside risk potential of --. On the other hand Standard BioTools has an analysts' consensus of $2.38 which suggests that it could grow by 119.91%. Given that Standard BioTools has higher upside potential than Weed, analysts believe Standard BioTools is more attractive than Weed.

Weed has a beta of 0.835, which suggesting that the stock is 16.517% less volatile than S&P 500. In comparison Standard BioTools has a beta of 1.804, suggesting its more volatile than the S&P 500 by 80.443%.

Weed has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Standard BioTools offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Weed pays -- of its earnings as a dividend. Standard BioTools pays out -- of its earnings as a dividend.

Weed quarterly revenues are --, which are smaller than Standard BioTools quarterly revenues of $40.8M. Weed's net income of -$95.9K is higher than Standard BioTools's net income of -$26M. Notably, Weed's price-to-earnings ratio is 180.00x while Standard BioTools's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Weed is -- versus 2.38x for Standard BioTools. Usually stocks with elevated PS ratios are considered overvalued.

McKesson has a net margin of -- compared to Weed's net margin of 1.39%. Weed's return on equity of -- beat McKesson's return on equity of --.

Weed has a consensus price target of --, signalling downside risk potential of --. On the other hand McKesson has an analysts' consensus of $744.58 which suggests that it could grow by 2.82%. Given that McKesson has higher upside potential than Weed, analysts believe McKesson is more attractive than Weed.

Weed has a beta of 0.835, which suggesting that the stock is 16.517% less volatile than S&P 500. In comparison McKesson has a beta of 0.525, suggesting its less volatile than the S&P 500 by 47.469%.

Weed has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. McKesson offers a yield of 0.38% to investors and pays a quarterly dividend of $0.71 per share. Weed pays -- of its earnings as a dividend. McKesson pays out 10.47% of its earnings as a dividend. McKesson's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Weed quarterly revenues are --, which are smaller than McKesson quarterly revenues of $90.8B. Weed's net income of -$95.9K is lower than McKesson's net income of $1.3B. Notably, Weed's price-to-earnings ratio is 180.00x while McKesson's PE ratio is 28.04x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Weed is -- versus 0.26x for McKesson. Usually stocks with elevated PS ratios are considered overvalued.

Pineapple has a net margin of -- compared to Weed's net margin of --. Weed's return on equity of -- beat Pineapple's return on equity of --.

Weed has a consensus price target of --, signalling downside risk potential of --. On the other hand Pineapple has an analysts' consensus of -- which suggests that it could fall by --. Given that Weed has higher upside potential than Pineapple, analysts believe Weed is more attractive than Pineapple.

Weed has a beta of 0.835, which suggesting that the stock is 16.517% less volatile than S&P 500. In comparison Pineapple has a beta of 36.643, suggesting its more volatile than the S&P 500 by 3564.318%.

Weed has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Pineapple offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Weed pays -- of its earnings as a dividend. Pineapple pays out -- of its earnings as a dividend.

Weed quarterly revenues are --, which are smaller than Pineapple quarterly revenues of --. Weed's net income of -$95.9K is higher than Pineapple's net income of --. Notably, Weed's price-to-earnings ratio is 180.00x while Pineapple's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Weed is -- versus 32.06x for Pineapple. Usually stocks with elevated PS ratios are considered overvalued.